May 20, 2021
VIA EDGAR SUBMISSION
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
|
Re: |
Navidea Biopharmaceuticals, Inc. (the “Company”) |
Dear Ladies and Gentlemen:
Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Monday, May 24, 2021, at 6:00 a.m., Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact our outside counsel, Faith L. Charles of Thompson Hine LLP, at (212) 908-3905, or Kaoru Suzuki at (513) 352-6569. Please also call Faith L. Charles or Kaoru Suzuki as soon as the Company’s Registration Statement on Form S-1 has been declared effective. Thank you for your attention to this matter.
|
Sincerely,
NAVIDEA BIOPHARMACEUTICALS, INC. |
||
| By: | /s/ Jed A. Latkin | |
| Name: | Jed A. Latkin | |
| Title: |
Chief Executive Officer, Chief Financial Officer and Chief Operating Officer |
|
|
cc: |
Faith L. Charles, Thompson Hine LLP |
|
|
Kaoru Suzuki, Thompson Hine LLP |